| Literature DB >> 15735745 |
Vladimir J N Bykov1, Nicole Zache, Helene Stridh, Jacob Westman, Jan Bergman, Galina Selivanova, Klas G Wiman.
Abstract
Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15735745 DOI: 10.1038/sj.onc.1208419
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867